66

GC01, a first-in-class antimitotic peptide for the treatment of glioblastoma, is being developed by GlioCure, a preclinical drug development company specializing in neuro-oncology. Glioblastoma is the most common and aggressive tumor of the nervous system with ∼ 200,000 deaths per year worldwide (∼ 17,000/year in Europe) and a median survival of 14–16 months. Despite current treatments consisting of tumor resection followed by radiation/chemotherapy, tumor recurrence is systematic due to significant cellular heterogeneity in these tumors and resistance to standard treatments, particularly due to glioblastoma stem cells that escape treatment. With its specific antimitotic activity involving βIII-tubulin, GC01 offers a potent and specific anti-glioblastoma mechanism of action, making it a potential treatment to address the urgent and unmet medical needs for this indication. Preclinical work conducted to date has demonstrated significant antitumor activity both in vitro and in vivo, as well as an absence of toxicity in healthy tissues. GlioCure is currently completing the non-regulatory preclinical development of GC01 and its pharmaceutical development in order to initiate the regulatory preclinical studies for authorization of a first clinical trial. GlioCure is also working to demonstrate the therapeutic potential of GC01 for other cancers of the nervous system, such as high-grade pediatric gliomas and brain metastases.